Abstract:The discovery of hypoxia-inducible factor-1 has led to a rapidly increasing understanding of the molecular mechanism of tumor hypoxia in the past two decades. Today it is generally accepted that HIF-1 plays a pivotal role in the cellular response to tumor hypoxia which represents a major obstacle to the success of radiotherapy and chemotherapy. Meanwhile, many details involved in the expression, accumulation and transactivation of HIF-1 have been well elucidated. Targeting HIF-1 has become a novel and efficient strategy for cancer therapy and a number of agents have been developed aiming to suppress HIF-1. This review will concisely introduce the general knowledge on the molecular biology of HIF-1 and possible targets along the HIF-1 pathway. Moreover, a number of compounds reported with anti-HIF-1 activity are included and mainly classified as direct and indirect inhibitors based on their different modes of action. While direct HIF-1 inhibitors prevent HIF-1 from transactivation, DNA binding and subsequently initiating transcriptional activity, indirect HIF-1 inhibitors generally block the transcription or translation of HIF-1α or promote the degradation of HIF-1α protein. According to different structural features, direct HIF-1 inhibitors are divided into several groups: polyamides, quinols and naphthoquinone spiroketal analogues, shikonin derivatives, epidithiodiketopiperazines, and two representative drugs: echinomycin and bortezomib. In the same way, indirect inhibitors comprise the following classes: polyphenols, benzoazaheterocycles, rapamycins, camptothecins, geldanamycins, (aryloxyacetylamino)benzoic acid analogues, 2-methoxyestradiol and analogues, hydroxamic acid compounds and others. The rest with mechanism still not so clear would also be listed and introduced, with an emphasis on the marinederived natural products. The in vitro and/or in vivo activities of these compounds and their mechanisms of HIF-1 inhibition would be discussed and the SARs of unique structural types of HIF-1 inhibitors will be briefly concluded.

HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies

HIF-1α pathway: role, regulation and intervention for cancer therapy

Knockdown of Hypoxia-Inducible Factor 1α (Hif-1Α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (pi3k)/akt/mammalian Target of Rapamycin (mtor) Signaling Pathway in Ovarian Cancer Cells

Expression of Hypoxia-Inducible Factor-1Α in Ovarian Cancer and Its Clinical Significance

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Recent Progress in the Study on Antitumor Drugs Targeting Hypoxia-Inducible Factor-1

[Hypoxia-Inducible Factor-1Alpha: a Promising Target for Tumor Therapy].

Recent Agents Targeting Hif-1 Alpha For Cancer Therapy

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

Small Molecules Targeting HIF-1α Pathway for Cancer Therapy in Recent Years

Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management

Hypoxia-inducible factor 1α (HIF-1α) correlated with tumor growth and apoptosis in ovarian cancer

Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy

New Developments in Molecular Targeted Therapy of Ovarian Cancer.

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

HIF-1α Activates Hypoxia-Induced MXRA5 Expression in the Progression of Ovarian Cancer